Quick orientationEvidence update: 6 October 2026
What is Selank?
Selank is a synthetic peptide related to tuftsin and is usually discussed for anxiety, stress and calmer concentration.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Small human studies and preclinical work; international evidence base remains limited.
What the mechanism suggests
Synthetic tuftsin analogue studied for anxiolytic and neurochemical effects, often by intranasal routes in regional research.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Synthetic tuftsin analogue studied for anxiolytic and neurochemical effects, often by intranasal routes in regional research.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Selank versus medazepam in anxiety/neurasthenia — 2008
Comparative clinical study · 62 patientsThirty patients received Selank and 32 medazepam. The paper reported similar anxiolytic effects, with additional antiasthenic/psychostimulant effects attributed to Selank.
There is human clinical literature, but it is small, regional and not comparable in depth to modern multinational drug programmes.
What it doesn't prove: Older Russian-language study, modest sample and limited independent replication.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Published human GAD dosing 2,70 | 0 mcg/day intranasal, delivered as nine Stud | y-specific | Fixed daily total | 20-patient human study, as |
| 300 | mcg administrations across the study day | reported in evidence review | ||
| Human evidence caveat | Several human papers exist but most abstracts do not expose dose; Russian full texts can be difficult to retrieve | — | — | Limited accessible dose documentation |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Low nasal pattern | 100–300 mcg intranasal once or twice daily | 1–3 weeks | Usually fixed | Community |
| Common daily-total pattern | ~300–900 mcg/day intranasal, divided | 1–3 weeks | May split into 2–3 administrations | Community |
| Higher research-adjacent total | ~2.7 mg/day intranasal divided | Study-specific / short course | Nine 300 mcg administrations in reported human study | Human-study amount, not a community recommendation |
Selank is a good candidate for PP's 'source transparency' model: one human dose is unusually specific, while much of the online 100–600 mcg advice is community convention rather than a clearly documented clinical regimen.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Not an established general treatment for anxiety or cognition.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
There is human clinical literature, but it is small, regional and not comparable in depth to modern multinational drug programmes.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.